Table 13. Final health outcomes in randomized controlled trials evaluating nonmajor orthopedic surgery

| Study, Year | Group | Symptomatic objectively confirmed VTE n/N | Major VTE  n/N | Fatal PE n/N | Non- fatal PE  n/N | PE  n/N | PTS  n/N | Mortality  n/N | Mortality due to bleeding n/N |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lapidus, 2007 | Dalteparin | --- | --- | 0/52 | 0/52 | 0/52 | --- | --- | --- |
|  | Placebo | --- | --- | 0/53 | 0/53 | 0/53 | --- | --- | --- |
| Michot, 2002 | Dalteparin | --- | --- | --- | --- | 1/66 | --- | --- | --- |
|  | Control | --- | --- | --- | --- | 0/64 | --- | --- | --- |

Abbreviations: n/N= total number of events/total population; PE=pulmonary embolism; PTS=post thrombotic syndrome; VTE=venous thromboembolism